Tyme Stock Is Trading Higher On Pipeline Update After Strategic Review, Q4 Earnings
Tyme Technologies Inc (NASDAQ:TYME) announced a breast cancer trial with Georgetown University named OASIS. Enrollment is expected to start in Q3…
Novan’s Stock Surges As SB206 Can Potentially Shorten Duration Of Contagious Skin Disease
Novan Inc (NASDAQ:NOVN) has announced positive topline efficacy and safety results from the B-SIMPLE4 Phase 3 trial evaluating SB206, a topical…
Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes
Precigen Inc’s (NASDAQ:PGEN) subsidiary Precigen ActoBio announced topline results from the Phase 1b/2a study evaluating AG019 ActoBiotics to treat recent-onset type…
Despite Hitting Mid-Stage Trial Endpoint Goal, Vertex Strikes Out Rare Lung Disease Candidate; Stock Tumbles
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced the Phase 2 data evaluating VX-864 in alpha-1 antitrypsin deficiency (AATD) with the PiZZ genotype.
With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch
Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm.
BofA Downgrades Clover Health After 100% Stock Surge
Clover Health Investments Corp.’s (NASDAQ: CLOV) stock has spiked by around 100% over the past week and is now at a 70% premium to its closest competitor, Alignment Healthcare Inc (NASDAQ: ALHC), according to BofA
HAVN Life is Looking for a Safe Haven to Mental Health Through Psychedelic Medicine
Most companies' success stories come as a result of wanting to accomplish a greater purpose. For HAVN Life Sciences Inc. (CSE: HAVN) (OTC PINK: HAVLF) (FSE: 5NP) CEO Tim Moore, his personal experience took him to explore alternatives beyond traditional pharma.
‘No Obamacare ruling today. The court issued one opinions relating to the Armed Career Criminal Act’ -Tweet From Bloomberg Law Reporter
https://twitter.com/WheelerLydia/status/1402989730522755085
Amgen’s Stomach Cancer Drug Acquired in Five Prime Buyout Extends Patients’ Lives, Mid-Stage Study Shows
Amgen Inc (NASDAQ:AMGN) has announced updated results for investigational bemarituzumab combined with chemotherapy from the Phase 2 FIGHT trial in patients…